Endo International plc (OTC: ENDPQ), an American-Irish specialty pharmaceutical company, announced on Thursday that one of its operating companies, Par Pharmaceutical, Inc, has started shipping colchicine 0.6mg capsules, a generic version of Hikma's MITIGARE.
The product is intended for prophylaxis of gout flares in adults. It is the first generic colchicine capsule approved by the US Food and Drug Administration.
Scott Sims, Endo senior vice president and general manager, Injectable Solutions & Generics, said, 'We are pleased to offer this high-quality, affordable medication. As a reliable supplier of generic products, we take pride in providing choices to appropriate patients.'
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines